22 April 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Department
Michał Machowski
1ABCDEF, Aisha Ou-Pokrzewińska1BCDEF, Katarzyna Perzanowska-Brzeszkiewicz 1BCDEF, Magdalena Gałecka-Nowak 1BDE, Szymon Pacho1BDE, Mateusz Jermakow 1BCDE*, Agnieszka Wójcik1BDE, Milena Zoruk1BDE, Andrzej Pruszczyk 1BDE, Karol Deutsch1BDE, Marek Roik 1BDE, Andrzej Łabyk 1BDE, Piotr Palczewski 2ABDEF, Piotr Pruszczyk 1ABCDEF
DOI: 10.12659/MSM.942612
Med Sci Monit 2024; 30:e942612
Table 1 Initial clinical and laboratory characteristics of total study group.
| Parameter [unit] | Value |
|---|---|
| Age [years] | 68.1 (13.9) |
| Male sex, n (%) | 159 (63.9) |
| Previous CAD, n (%) | 60 (24.1) |
| Previous CHF, n (%) | 51 (20.5) |
| COVID-19 pneumonia lung involvement [%] | 50.4 (24.9) |
| Procalcitonin [ng/ml] | 0.18 (0.08;0.50) |
| CRP [mg/dl] | 79.1 (34.73;147.8) |
| MEWS | 1.00 (1.00;2.00) |
| CAD – coronary artery disease; CHF – congestive heart failure; CRP – C-reactive protein; MEWS – Modified Early Warning Score. | |